Corium Announces Issuance of Key U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease
"Our novel Corplex TDS design and formulation technologies were enabling for the once-weekly transdermal delivery of Donepezil," said
The new patent is eligible for listing in the U.S. FDA Orange Book, and its life extends at least to July 2037. It is the first to issue of a series of pending Corium patent applications relating to various aspects of Corplex Donepezil, as well as similar products.
About Alzheimer's Disease and Donepezil
Alzheimer's disease is a progressive brain disorder in which the brain cells degenerate and die, causing a steady decline in memory and mental function. According to the Alzheimer’s Association, an estimated 5.7 million Americans are living with Alzheimer's disease in 2018; by 2050, this number is projected to rise to 13.8 million. Alzheimer's disease is the most common cause of dementia among older adults. Dementia ranges in severity from mild, when it is just beginning to affect a person's functioning, to moderate, and severe, when the person must depend on others for the basic activities of day-to-day life.
Donepezil (the active ingredient in Aricept®) is the most widely prescribed medication in a class of Alzheimer's drugs known as cholinesterase inhibitors, and is approved for the treatment of mild, moderate and severe disease. Donepezil is currently only available in tablet or orally disintegrating tablet form, each administered once daily, presenting compliance challenges for family members and caregivers who cannot rely on patients to consistently take their daily tablets, and is known to cause gastrointestinal side effects, including nausea, vomiting and loss of appetite.
Corium's Corplex system is a novel commercial-stage platform technology designed to broadly enable the transdermal delivery of small molecules, many of which have not previously been amenable to transdermal delivery. Corium's Corplex technology has been successfully commercialized in
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our products, intellectual property rights and portfolio, regulatory pathway, timing and plans, and the advancement of our technologies, proprietary products and product candidates. Forward-looking statements are based on management's current expectations and projections and are subject to risks and uncertainties, which may cause Corium's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Corium's business and its results are detailed in Corium's Quarterly Report on Form 10-Q for the quarter ended
Corplex™ and MicroCor® are trademarks of
Aricept® is a registered trademark of
Crest® Whitestrips is a registered trademark of The Procter & Gamble Company.
Investor and Media Contact:
Source: Corium International, Inc.